Australia has made a groundbreaking decision by becoming the first country to legalise the clinical prescribing of MDMA (ecstasy) and psilocybin (magic mushrooms) for the treatment of specific mental health disorders, including PTSD and treatment-resistant depression. Setting Australia apart as the pioneer in adopting psychoactive-based treatments for mental health, as of 1 July, authorised psychiatrists
Read More
The medicinal cannabis industry in Australia has been rapidly gaining momentum, reaching an estimated value of approximately $245 million in 2022 and is projected to maintain a strong CAGR of 16.71% from 2023 to 2027. While the availability of cannabis for general use remains restricted in Australia, the nation continues to attract cannabis manufacturing companies
Read More
Since the easing of regulatory red tape and wider societal acceptance of utilising cannabis for its medical properties, the medicinal cannabis industry has become an intense battleground as researchers have raced towards commercial products. In the case of Cann Group (ASX: CAN) though, they might have just triggered a land mine. Undertaking any form of
Read More
In an incident which can only be described with a 🤦♂️, shareholders of cannabis company Cann Group (ASX: CAN) are understandably frustrated in the Company which has reported a cybersecurity breach that resulted in $3.6 million going missing. The incident was discovered on 4 February and immediately led Cann to enter a trading halt as
Read More
Medical cannabis producer, Cann Group Limited (ASX: CAN) have announced this morning their response to yesterday’s price query from the ASX that lead to the company being placed in a trading halt soon after. The regulator probed the company to ‘please explain’ yesterday’s trading activity which saw almost a 19% increase in trading price and
Read More